Intralesional triamcinolone acetonide injection is one of the most-used tools in dermatology, for keloids and hypertrophic scars, cystic acne, discoid lupus, and, relevant to our alopecia areata overview, one of the first-line treatments for limited patchy hair loss. It's also been sitting on the FDA's drug shortage list for more than five years, one of the longest-running shortages a dermatology pharmacist is likely to encounter, and a real-world illustration of how the 503A vs. 503B shortage-compounding exception plays out over the long term.

A Shortage That Wouldn't Resolve

Triamcinolone acetonide injectable suspension shortages trace back to manufacturing and supply issues affecting multiple producers. The branded ophthalmic formulation, Triesence, went through its own version of this: Novartis divested it to Harrow Eye in late 2023 after manufacturing delays tied to good manufacturing practice (GMP) issues, with a relaunch targeted for 2024 that still hasn't fully met market demand. The broader injectable triamcinolone market, the formulation dermatology practices actually use for intralesional injections, has followed a similarly prolonged pattern.

Where Compounding Fits In

As long as triamcinolone acetonide injectable suspension remains on the FDA's active shortage list, the "essentially a copy" restriction on 503A compounding lifts for this drug, the same mechanism described in our 503A vs. 503B overview. That's meant a meaningful share of the intralesional triamcinolone used in dermatology practices over the past several years has been sourced from compounding, either patient-specific 503A preparations or office-use quantities from 503B outsourcing facilities, rather than the commercial branded product.

This is the same regulatory pathway that made headlines with semaglutide and tirzepatide compounding during the GLP-1 shortages: a shortage opens the door, and the door is legally tied to that shortage remaining active. The difference is duration. GLP-1 shortages resolved within a couple of years and triggered a fast, well-publicized wind-down. Triamcinolone's shortage has simply persisted, which means the compounding pathway for it has stayed open far longer, and far more quietly.

Why This Still Deserves Active Attention

  • Persistent doesn't mean permanent. Shortages resolve on their own timeline, and when the FDA declares triamcinolone's shortage over, the same wind-down obligations that hit GLP-1 compounders will apply here.
  • Sourcing standards still matter. Whether a practice's intralesional triamcinolone comes from a 503A pharmacy or a 503B facility affects the quality assurance framework behind it, worth confirming rather than assuming.
  • It's a pattern, not a one-off. Between triamcinolone and the GLP-1 wind-down, dermatology-adjacent practice has now seen both ends of the shortage-compounding lifecycle: a shortage that closed quickly, and one that's stayed open for years. Recognizing which situation a given drug is in shapes how closely it needs monitoring.

This is an educational overview and does not constitute legal, regulatory, or pharmaceutical advice. Current FDA shortage status and 503A/503B rules should always be verified directly with the FDA and your state board of pharmacy before making compounding or sourcing decisions.

Sources:
ASHP Drug Shortages Database, "Triamcinolone Acetonide Injectable Suspension."
Modern Retina, "Harrow Provides Triamcinolone Acetonide Injectable Suspension Relaunch Update."